Sarepta Therapeutics · 18 hours ago
Business Operations Intern
Bedford, MA
Internship
Hybrid
Intern
$21/hr - $26/hrSarepta Therapeutics is a leader in genetic medicine, focusing on innovative therapies for Duchenne muscular dystrophy and other diseases. The Business Operations Intern will enhance operational efficiency and support strategic Quality initiatives while gaining exposure to real-world business operations in the biotech industry.
BiotechnologyGeneticsHealth CareTherapeutics
No H1B
Responsibilities
Monitoring and tracking progress toward Quality Business Operations 2026 objectives
Supporting Quality Assurance and Quality Control teams on Business Operations initiatives
Maintaining and updating tools, trackers, and business documentation within SharePoint
Assisting with communication and changing management processes
Managing small scale projects and engagements that enhance team efficiency
Maintaining organizational charts, resource lists, and cross functional inputs
Coordinating with suppliers on ad hoc queries and scheduling needs
Supporting the Data Management initiative using data science or mathematical skills
Providing general support to advance critical 2026 Quality objectives
Qualification
Required
Bachelor's degree candidates who have completed at least their sophomore year, ideally pursuing a degree in Business, Operations, Data Science, STEM, or a related discipline
Strong interest in business operations, process improvement, and cross‑functional collaboration
Highly organized, detail‑oriented, and able to manage multiple priorities
Strong written and verbal communication skills
Comfortable working with data and using tools for tracking, documentation, and reporting
Proactive mindset with curiosity and willingness to learn
Able to work independently and collaboratively in a dynamic environment
Benefits
Competitive compensation and benefit package
Company
Sarepta Therapeutics
Sarepta Therapeutics focuses on the discovery and development of precision genetic medicine to treat rare diseases.
Founded in 1980
501-1000 employees
Funding
Current Stage
Public CompanyTotal Funding
$2.88BKey Investors
Michael Andrew ChambersPharmakon AdvisorsMidCap Financial
2025-12-11Post Ipo Debt· $291.4M
2025-08-21Post Ipo Equity
2025-08-21Post Ipo Debt· $602M
Leadership Team
Ian Estepan
Executive Vice President, Chief Financial Officer
K
Kathy Behrens Wilsey
Director
Recent News
2026-01-24
Genetic Engineering News
2026-01-23
Company data provided by crunchbase